X

Trial Profile

A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Ribociclib (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

28 Apr 2020 Results (n=12) presented at the 111th Annual Meeting of the American Association for Cancer Research - I
20 May 2019 Status changed from recruiting to active, no longer recruiting.
05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com